137 related articles for article (PubMed ID: 31831802)
1. One-step artificial antigen presenting cell-based vaccines induce potent effector CD8 T cell responses.
Su Q; Igyártó BZ
Sci Rep; 2019 Dec; 9(1):18949. PubMed ID: 31831802
[TBL] [Abstract][Full Text] [Related]
2. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
3. Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses.
Li H; Shao S; Cai J; Burner D; Lu L; Chen Q; Minev B; Ma W
Immunology; 2017 Nov; 152(3):462-471. PubMed ID: 28664991
[TBL] [Abstract][Full Text] [Related]
4. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.
Accolla RS; Ramia E; Tedeschi A; Forlani G
Front Immunol; 2019; 10():1806. PubMed ID: 31417570
[TBL] [Abstract][Full Text] [Related]
5. Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination.
Haug M; Brede G; Håkerud M; Nedberg AG; Gederaas OA; Flo TH; Edwards VT; Selbo PK; Høgset A; Halaas Ø
Front Immunol; 2018; 9():650. PubMed ID: 29670624
[TBL] [Abstract][Full Text] [Related]
6. Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.
Harao M; Mittendorf EA; Radvanyi LG
BioDrugs; 2015 Feb; 29(1):15-30. PubMed ID: 25523015
[TBL] [Abstract][Full Text] [Related]
7. Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8⁺ T cells.
Muraoka D; Nishikawa H; Noguchi T; Wang L; Harada N; Sato E; Luescher I; Nakayama E; Kato T; Shiku H
Vaccine; 2013 Apr; 31(17):2110-8. PubMed ID: 23499606
[TBL] [Abstract][Full Text] [Related]
8. Selection of HLA-A2 restricted CML28 peptide by artificial antigen-presenting cells.
Mao H; Geng Z; Liu W; Sun H; Huang W
J Immunother; 2008 Jun; 31(5):487-90. PubMed ID: 18463536
[TBL] [Abstract][Full Text] [Related]
9. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses.
Yu X; He J; Mongkhoune S; Peng Y; Xie Y; Su J; Zhou SF; Xie XX; Luo GR; Fang Y; Li X; Li X; Zhou N; Zhao YX; Lu XL
Asian Pac J Trop Med; 2013 Jun; 6(6):467-72. PubMed ID: 23711708
[TBL] [Abstract][Full Text] [Related]
10. Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
Altvater B; Pscherer S; Landmeier S; Kailayangiri S; Savoldo B; Juergens H; Rossig C
Cancer Immunol Immunother; 2012 Mar; 61(3):385-96. PubMed ID: 21928126
[TBL] [Abstract][Full Text] [Related]
11. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
12. Efficient amplification of melanoma-specific CD8+ T cells using artificial antigen presenting complex.
Chang J
Exp Mol Med; 2006 Dec; 38(6):591-8. PubMed ID: 17202834
[TBL] [Abstract][Full Text] [Related]
13. Engineering anti-cancer nanovaccine based on antigen cross-presentation.
Warrier VU; Makandar AI; Garg M; Sethi G; Kant R; Pal JK; Yuba E; Gupta RK
Biosci Rep; 2019 Oct; 39(10):. PubMed ID: 31652460
[TBL] [Abstract][Full Text] [Related]
14. Tumor antigen presentation: changing the rules.
Armstrong TD; Pulaski BA; Ostrand-Rosenberg S
Cancer Immunol Immunother; 1998 Apr; 46(2):70-4. PubMed ID: 9558001
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
16. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
Front Immunol; 2018; 9():776. PubMed ID: 29867922
[TBL] [Abstract][Full Text] [Related]
17. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.
Hsu DH; Paz P; Villaflor G; Rivas A; Mehta-Damani A; Angevin E; Zitvogel L; Le Pecq JB
J Immunother; 2003; 26(5):440-50. PubMed ID: 12973033
[TBL] [Abstract][Full Text] [Related]
18. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
19. One-step shotgun approach for antigenic specific pMHCs capture stimulated CD8
Liu L; Li Y; Song Y; Sun Z; Li W; Li B; Wang Y; Wang H; Wang B
Cell Immunol; 2023; 393-394():104784. PubMed ID: 37984278
[TBL] [Abstract][Full Text] [Related]
20. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines.
Nair SK; Boczkowski D; Snyder D; Gilboa E
Eur J Immunol; 1997 Mar; 27(3):589-97. PubMed ID: 9079797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
